000			03916nam a22005657a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a1878-0938
024			_aS1553-8389(24)00459-7 [pii]
040			_aOvid MEDLINE(R)
099			_a38789343
245			_aCoronary microvascular dysfunction and cancer therapy-related cardiovascular toxicity.
251			_aCardiovascular Revascularization Medicine. 2024 May 07
252			_aCardiovasc Revasc Med. 2024 May 07
253			_aCardiovascular revascularization medicine : including molecular interventions
260			_c2024
260			_fFY2024
260			_p2024 May 07
265			_saheadofprint
265			_tPublisher
266			_d2024-08-07
266			_z2024/05/24 21:55
501			_aAvailable in print through MWHC library: 2002 - present
520			_aBACKGROUND: Coronary microvascular dysfunction (CMD) has been implicated as a potential mechanism in the pathophysiology of different clinical presentations, including ischemia and no obstructive coronary artery disease (INOCA), myocardial infarction and nonobstructive coronary arteries (MINOCA), stress cardiomyopathy, heart failure, and myocarditis. There are limited data about the role of CMD in cancer therapy-related cardiovascular toxicities.
520			_aCASE PRESENTATIONS: Four women with a diagnosis of active cancer receiving treatment who developed subsequent MINOCA or INOCA presented for cardiac catheterization. Upon coronary angiography showing no obstructive coronary arteries, coronary function testing was performed to evaluate for CMD.
520			_aCONCLUSIONS: CMD may play a role in cardiovascular toxicities. Further coronary physiology studies are needed to understand the mechanisms of cancer therapy-related cardiovascular toxicity and CMD, as well as optimal preventive and treatment options. Copyright © 2024. Published by Elsevier Inc.
520			_aMETHODS: Coronary physiology was assessed measuring non-hyperemic (resting full-cycle ratio [RFR]) and hyperemic (fractional flow reserve [FFR]) indices using a physiologic pressure wire. The wire also measured coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and RFR using thermodilution technology. CMD was confirmed if the CFR was <2.5 and the IMR was >25.
520			_aRESULTS: Among 4 patients with diagnosis of active cancer presenting with chest pain, there was no evidence of obstructive coronary artery disease, leading to separate diagnoses of INOCA, MINOCA, stress cardiomyopathy, and myocarditis. We found CMD in 2 patients (1 with INOCA and 1 with immune checkpoint inhibitor-related myocarditis).
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
650			_zAutomated
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aAdvanced Cardiac Catheterization Research Fellowship
656			_aCardiac Oncology Fellowship
657			_aCase Reports
700			_aAbusnina, Waiel _bMWHC _cAdvanced Cardiac Catheterization Research Fellowship _dMBBCh
700			_aBarac, Ana _bMHVI
700			_aBen-Dor, Itsik _bMHVI
700			_aBhogal, Sukhdeep _bMHVI
700			_aCase, Brian C _bMHVI
700			_aChaturvedi, Abhishek _bMWHC _cAdvanced Cardiac Catheterization Research Fellowship _dMBBS
700			_aChitturi, Kalyan _bMWHC _cAdvanced Cardiac Catheterization Research Fellowship _dDO
700			_aHashim, Hayder _bMHVI
700			_aKassaian, Seyed Ebrahim _bMWHC _cCardiac Oncology Fellowship _dMD
700			_aMerdler, Ilan _bMHVI
700			_aWaksman, Ron _bMHVI
790			_aChitturi KR, Bhogal S, Kassaian SE, Merdler I, Abusnina W, Chaturvedi A, Ben-Dor I, Waksman R, Case BC, Barac A, Hashim HD
856			_uhttps://dx.doi.org/10.1016/j.carrev.2024.05.001 _zhttps://dx.doi.org/10.1016/j.carrev.2024.05.001
942			_cART _dArticle
999			_c14419 _d14419